State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, China.
The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China.
Proc Natl Acad Sci U S A. 2023 Jan 24;120(4):e2202820120. doi: 10.1073/pnas.2202820120. Epub 2023 Jan 18.
Human coronavirus 229E (HCoV-229E) and NL63 (HCoV-NL63) are endemic causes of upper respiratory infections such as the "common cold" but may occasionally cause severe lower respiratory tract disease in the elderly and immunocompromised patients. There are no approved antiviral drugs or vaccines for these common cold coronaviruses (CCCoV). The recent emergence of COVID-19 and the possible cross-reactive antibody and T cell responses between these CCCoV and SARS-CoV-2 emphasize the need to develop experimental animal models for CCCoV. Mice are an ideal experimental animal model for such studies, but are resistant to HCoV-229E and HCoV-NL63 infections. Here, we generated 229E and NL63 mouse models by exogenous delivery of their receptors, human hAPN and hACE2 using replication-deficient adenoviruses (Ad5-hAPN and Ad5-hACE2), respectively. Ad5-hAPN- and Ad5-hACE2-sensitized IFNAR and STAT1 mice developed pneumonia characterized by inflammatory cell infiltration with virus clearance occurring 7 d post infection. Ad5-hAPN- and Ad5-hACE2-sensitized mice generated virus-specific T cells and neutralizing antibodies after 229E or NL63 infection, respectively. Remdesivir and a vaccine candidate targeting spike protein of 229E and NL63 accelerated viral clearance of virus in these mice. 229E- and NL63-infected mice were partially protected from SARS-CoV-2 infection, likely mediated by cross-reactive T cell responses. Ad5-hAPN- and Ad5-hACE2-transduced mice are useful for studying pathogenesis and immune responses induced by HCoV-229E and HCoV-NL63 infections and for validation of broadly protective vaccines, antibodies, and therapeutics against human respiratory coronaviruses including SARS-CoV-2.
人冠状病毒 229E(HCoV-229E)和 NL63(HCoV-NL63)是引起上呼吸道感染(如“普通感冒”)的地方性病原体,但偶尔也会导致老年人和免疫功能低下患者发生严重的下呼吸道疾病。目前尚无针对这些普通感冒冠状病毒(CCCoV)的批准抗病毒药物或疫苗。最近 COVID-19 的出现以及这些 CCCoV 与 SARS-CoV-2 之间可能存在的交叉反应性抗体和 T 细胞反应,强调了开发 CCCoV 实验动物模型的必要性。小鼠是此类研究的理想实验动物模型,但对 HCoV-229E 和 HCoV-NL63 感染具有抗性。在这里,我们分别使用复制缺陷型腺病毒(Ad5-hAPN 和 Ad5-hACE2),通过外源性递送人冠状病毒的受体,即人 APN 和 ACE2,生成了 229E 和 NL63 小鼠模型。Ad5-hAPN 和 Ad5-hACE2 敏化的 IFNAR 和 STAT1 小鼠发生肺炎,特征为感染后 7 天病毒清除时炎症细胞浸润。Ad5-hAPN 和 Ad5-hACE2 敏化的小鼠在感染 229E 或 NL63 后分别产生了病毒特异性 T 细胞和中和抗体。瑞德西韦和针对 229E 和 NL63 刺突蛋白的疫苗候选物加速了这些小鼠中的病毒清除。229E 和 NL63 感染的小鼠对 SARS-CoV-2 感染部分具有保护作用,可能由交叉反应性 T 细胞反应介导。Ad5-hAPN 和 Ad5-hACE2 转导的小鼠可用于研究 HCoV-229E 和 HCoV-NL63 感染引起的发病机制和免疫反应,以及验证针对包括 SARS-CoV-2 在内的人类呼吸道冠状病毒的广泛保护性疫苗、抗体和治疗方法。